DK3237005T3 - Bispecific tetravalent antibodies and methods of making and using thereof - Google Patents

Bispecific tetravalent antibodies and methods of making and using thereof Download PDF

Info

Publication number: DK3237005T3
Authority: DK; Denmark
Prior art keywords: making; methods; tetravalent antibodies; bispecific tetravalent; bispecific
Prior art date: 2014-12-22

Application number

DK15874216.3T

Other languages

English (en)

Inventor

Zeren Gao

phil Tan

Brian Kovacevich

Blair Renshaw

Jeffrey Adamo

Nga Sze Amanda Mak

Shi Zhuo

Lan Chen

Yi Zhu

Original Assignee

Systimmune Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-22

Filing date

2015-12-19

Publication date

2024-11-18

2015-12-19 Application filed by Systimmune Inc filed Critical Systimmune Inc

2024-11-18 Application granted granted Critical

2024-11-18 Publication of DK3237005T3 publication Critical patent/DK3237005T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK15874216.3T 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of making and using thereof DK3237005T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462095348P	2014-12-22	2014-12-22
PCT/US2015/066951 WO2016106157A1 (en)	2014-12-22	2015-12-19	Bispecific tetravalent antibodies and methods of makiing and using thereof

Publications (1)

Publication Number	Publication Date
DK3237005T3 true DK3237005T3 (en)	2024-11-18

Family

ID=56151464

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15874216.3T DK3237005T3 (en)	2014-12-22	2015-12-19	Bispecific tetravalent antibodies and methods of making and using thereof

Country Status (22)

Country	Link
US (2)	US10919977B2 (da)
EP (3)	EP3237006B1 (da)
JP (2)	JP6947639B2 (da)
KR (3)	KR102590385B1 (da)
CN (11)	CN113512121B (da)
AU (1)	AU2015369831B2 (da)
CA (2)	CA2969867C (da)
DK (1)	DK3237005T3 (da)
ES (2)	ES2962675T3 (da)
FI (1)	FI3237005T3 (da)
HR (1)	HRP20241502T1 (da)
HU (1)	HUE069256T2 (da)
IL (3)	IL286835B2 (da)
LT (1)	LT3237005T (da)
NZ (1)	NZ732628A (da)
PL (1)	PL3237005T3 (da)
PT (1)	PT3237005T (da)
RS (1)	RS66070B1 (da)
SG (1)	SG11201704741PA (da)
SI (1)	SI3237005T1 (da)
SM (1)	SMT202400477T1 (da)
WO (2)	WO2016106157A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3237005T (lt) *	2014-12-22	2024-11-11	Systimmune, Inc.	Bispecifiniai tetravalentiniai antikūnai ir jų gamybos bei naudojimo būdai
AU2016206707A1 (en) *	2015-01-14	2017-08-10	Compass Therapeutics Llc	Multispecific immunomodulatory antigen-binding constructs
CN106632681B (zh) *	2016-10-11	2017-11-14	北京东方百泰生物科技有限公司	抗egfr和抗cd3双特异抗体及其应用
CN108948195B (zh) *	2017-05-23	2022-05-31	胡毅	一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
EP3645741A4 (en) *	2017-06-25	2021-08-25	Systimmune, Inc.	ANTI-4-1BB ANTIBODIES AND METHOD OF MANUFACTURING AND USING
CN117343193A (zh) *	2017-11-02	2024-01-05	西雅图免疫公司	双特异性抗体及其制备和使用方法
WO2019137548A1 (en) *	2018-01-15	2019-07-18	Nanjing Legend Biotech Co., Ltd.	Antibodies and variants thereof against tigit
CN108220244A (zh) *	2018-01-18	2018-06-29	东北农业大学	一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
CN107974461A (zh) *	2018-01-18	2018-05-01	东北农业大学	一种高效表达anti-hEGFR基因的真核表达载体构建方法
EP3774914A2 (en) *	2018-04-13	2021-02-17	Affimed GmbH	Nk cell engaging antibody fusion constructs
JP7475054B2 (ja) *	2018-05-16	2024-04-26	アーベルリミテッド	二重特異性抗体の組成物及びその使用方法
EP3833690B1 (en) *	2018-08-08	2024-03-27	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	Recombinant bifunctional protein targeting cd47 and her2
CN110850068B (zh) *	2018-08-21	2023-08-15	上海恒润达生生物科技股份有限公司	一种嵌合抗原受体亲和力检测方法
CN113301919B (zh) *	2018-11-13	2025-01-28	Jn生物科学有限责任公司	激活免疫细胞的双特异性抗体
KR20220038767A (ko) *	2019-07-26	2022-03-29	에이비엘바이오 주식회사	항-egfr/항-4-1bb 이중 특이 항체 및 이의 용도
BR112022002067A2 (pt) *	2019-08-08	2022-06-14	Regeneron Pharma	Formatos de molécula de ligação ao antígeno
WO2021168194A1 (en) *	2020-02-19	2021-08-26	Denali Therapeutics Inc.	Engineered anti-her2 bispecific proteins
TW202200619A (zh) *	2020-03-17	2022-01-01	美商西雅圖免疫公司	引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
CN111548424A (zh) *	2020-06-05	2020-08-18	上海科弈药业科技有限公司	一种靶向egfr与cd47的多功能融合蛋白及其应用
KR20230117330A (ko) *	2020-09-21	2023-08-08	시스트이뮨, 인코포레이티드	특이성이 개선된 이중특이적 항체(seba)
KR20240049339A (ko) *	2021-08-25	2024-04-16	시스트이뮨, 인코포레이티드	Egfr 및 her3를 표적으로 하는 이중특이적 4가 항체
EP4405396A2 (en) *	2021-09-20	2024-07-31	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
CN118302192A (zh) *	2021-10-03	2024-07-05	西雅图免疫公司	治疗癌症的方法及其药物组合物
MX2024005831A (es) *	2021-11-15	2024-07-09	Systimmune Inc	Conjugado de anticuerpo biespecifico-farmaco de camptotecina y uso farmaceutico del mismo.
WO2023241480A1 (zh) *	2022-06-13	2023-12-21	三优生物医药(上海)有限公司	抗pd-l1、vegf和egfr三特异性抗体及其应用
WO2024050439A2 (en) *	2022-08-31	2024-03-07	Systimmune, Inc.	Biepitopic tetravalent antibody targeting egfr
CN116063564A (zh) *	2022-10-08	2023-05-05	盛禾(中国)生物制药有限公司	一种纯化融合蛋白的方法
CN118829655A (zh) *	2023-02-15	2024-10-22	浙江时迈药业有限公司	Egfr和lag3双靶向的双特异性抗体及其用途
WO2025011470A1 (en) *	2023-07-07	2025-01-16	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Egfr/c-met bispecific binding protein and use thereof
WO2025026282A1 (en) *	2023-07-29	2025-02-06	Shanghai Kaijin Biotechnology, Ltd	Modified type e multi-specific antibodies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2200753B (en)	1986-12-23	1991-01-23	Brookes & Gatehouse	Speed measurement device
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
EP1472275B1 (en) *	2002-02-05	2008-12-17	Genentech, Inc.	Protein purification
US7332585B2 (en) *	2002-04-05	2008-02-19	The Regents Of The California University	Bispecific single chain Fv antibody molecules and methods of use thereof
ZA200702427B (en) *	2004-09-17	2008-12-31	Domantis Ltd	Compositions monovalent for CD40L binding and methods of use
WO2007147001A2 (en) *	2006-06-14	2007-12-21	Imclone Systems Incorporated	Lyophilized formulations of anti-egfr antibodies
AU2007353412A1 (en) *	2006-11-21	2008-11-20	Fox Chase Cancer Center	Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
CN102356092B (zh) *	2009-03-20	2014-11-05	霍夫曼-拉罗奇有限公司	双特异性抗-her抗体
US20120134993A1 (en)	2009-03-27	2012-05-31	Zymogenetics, Inc.	Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
EP2414391B1 (en) *	2009-04-02	2018-11-28	Roche Glycart AG	Multispecific antibodies comprising full length antibodies and single chain fab fragments
CN102378768A (zh)	2009-04-07	2012-03-14	罗氏格黎卡特股份公司	双特异性抗-ErbB-3/抗-c-Met抗体
PE20121530A1 (es) *	2009-09-01	2012-12-22	Abbvie Inc	Inmunoglobulinas con dominio variable dual
US10208128B2 (en) *	2009-11-04	2019-02-19	Affibody Ab	HER3 binding polypeptides
CA2811747A1 (en) *	2010-09-30	2012-04-05	Merck Sharp & Dohme Corp.	Generation, characterization and uses thereof of anti-her3 antibodies
CN103384681B (zh) *	2010-12-23	2018-05-18	霍夫曼-拉罗奇有限公司	结合剂
TWI622597B (zh)	2011-03-28	2018-05-01	賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
CN103796678B (zh)	2011-04-20	2018-02-27	健玛保	针对her2的双特异性抗体
US20140170148A1 (en) *	2011-04-20	2014-06-19	Genmab A/S	Bispecific antibodies against her2
SI2703486T1 (en) *	2011-04-25	2018-05-31	Daiichi Sankyo Company, Limited	ANTI-B7-H3 PROTITELO
CN102250246A (zh)	2011-06-10	2011-11-23	常州亚当生物技术有限公司	抗VEGF/PDGFRβ双特异性抗体及其应用
CN102250247B (zh)	2011-06-15	2013-06-19	常州亚当生物技术有限公司	一种抗vegf/ang2双特异性抗体及其应用
LT2794658T (lt) *	2011-12-19	2017-05-10	Synimmune Gmbh	Bispecifinė antikūno molekulė
US8961971B2 (en) *	2011-12-22	2015-02-24	Development Center For Biotechnology	Bispecific T-cell activator antibody
EP2831115A1 (en) *	2012-03-27	2015-02-04	F. Hoffmann-La Roche AG	Diagnosis and treatments relating to her3 inhibitors
IN2015DN01115A (da) *	2012-07-13	2015-06-26	Zymeworks Inc
CN104955838B (zh) *	2012-11-21	2021-02-02	詹森生物科技公司	双特异性EGFR/c-Met抗体
CN104650113A (zh) *	2012-12-21	2015-05-27	百奥泰生物科技(广州)有限公司	类美登素衍生物及其制备方法和用途
MX2015012059A (es)	2013-03-15	2016-01-12	Merck Patent Gmbh	Anticuerpos biespecificos tetravalentes.
CN104211814A (zh) *	2013-05-29	2014-12-17	三星电子株式会社	用于消耗靶膜蛋白的组合物
LT3237005T (lt)	2014-12-22	2024-11-11	Systimmune, Inc.	Bispecifiniai tetravalentiniai antikūnai ir jų gamybos bei naudojimo būdai

2015
- 2015-12-19 LT LTEPPCT/US2015/066951T patent/LT3237005T/lt unknown
- 2015-12-19 CN CN202110471052.7A patent/CN113512121B/zh active Active
- 2015-12-19 CN CN202110471392.XA patent/CN113105553B/zh active Active
- 2015-12-19 CA CA2969867A patent/CA2969867C/en active Active
- 2015-12-19 CN CN202311507433.1A patent/CN117467017A/zh active Pending
- 2015-12-19 HR HRP20241502TT patent/HRP20241502T1/hr unknown
- 2015-12-19 WO PCT/US2015/066951 patent/WO2016106157A1/en active Application Filing
- 2015-12-19 IL IL286835A patent/IL286835B2/en unknown
- 2015-12-19 CN CN202110470743.5A patent/CN113105551B/zh active Active
- 2015-12-19 EP EP15874217.1A patent/EP3237006B1/en active Active
- 2015-12-19 ES ES15874217T patent/ES2962675T3/es active Active
- 2015-12-19 JP JP2017551580A patent/JP6947639B2/ja active Active
- 2015-12-19 CN CN201580073430.9A patent/CN107206074B/zh active Active
- 2015-12-19 KR KR1020237021346A patent/KR102590385B1/ko active Active
- 2015-12-19 KR KR1020237034930A patent/KR20230149328A/ko active Pending
- 2015-12-19 US US15/119,694 patent/US10919977B2/en active Active
- 2015-12-19 RS RS20241150A patent/RS66070B1/sr unknown
- 2015-12-19 CN CN202110471245.2A patent/CN113512123B/zh active Active
- 2015-12-19 DK DK15874216.3T patent/DK3237005T3/da active
- 2015-12-19 AU AU2015369831A patent/AU2015369831B2/en active Active
- 2015-12-19 FI FIEP15874216.3T patent/FI3237005T3/fi active
- 2015-12-19 US US15/538,189 patent/US10717783B2/en active Active
- 2015-12-19 ES ES15874216T patent/ES2995733T3/es active Active
- 2015-12-19 SI SI201532042T patent/SI3237005T1/sl unknown
- 2015-12-19 KR KR1020177020104A patent/KR102548827B1/ko active Active
- 2015-12-19 EP EP15874216.3A patent/EP3237005B1/en active Active
- 2015-12-19 PL PL15874216.3T patent/PL3237005T3/pl unknown
- 2015-12-19 IL IL305193A patent/IL305193A/en unknown
- 2015-12-19 SG SG11201704741PA patent/SG11201704741PA/en unknown
- 2015-12-19 SM SM20240477T patent/SMT202400477T1/it unknown
- 2015-12-19 PT PT158742163T patent/PT3237005T/pt unknown
- 2015-12-19 CA CA3138083A patent/CA3138083A1/en active Pending
- 2015-12-19 CN CN202110470818.XA patent/CN113512120B/zh active Active
- 2015-12-19 CN CN202110471476.3A patent/CN113150165B/zh active Active
- 2015-12-19 HU HUE15874216A patent/HUE069256T2/hu unknown
- 2015-12-19 CN CN202110471082.8A patent/CN113512122B/zh active Active
- 2015-12-19 CN CN201580036408.7A patent/CN106659779B/zh active Active
- 2015-12-19 CN CN202110470781.0A patent/CN113105552B/zh active Active
- 2015-12-19 NZ NZ732628A patent/NZ732628A/en unknown
- 2015-12-19 WO PCT/US2015/066952 patent/WO2016106158A1/en active Application Filing
- 2015-12-19 EP EP24200270.7A patent/EP4491195A3/en active Pending
2017
- 2017-06-11 IL IL252811A patent/IL252811B/en unknown
2021
- 2021-04-15 JP JP2021068859A patent/JP7335290B2/ja active Active

Also Published As

Publication number	Publication date
ES2995733T3 (en)	2025-02-11
EP3237006B1 (en)	2023-08-16
CN107206074B (zh)	2023-12-01
CN113512120B (zh)	2024-08-02
CA3138083A1 (en)	2016-06-30
ES2962675T3 (es)	2024-03-20
KR102590385B1 (ko)	2023-10-18
JP6947639B2 (ja)	2021-10-13
WO2016106157A1 (en)	2016-06-30
US20170073418A1 (en)	2017-03-16
IL286835B2 (en)	2024-03-01
SI3237005T1 (sl)	2025-02-28
EP3237005A1 (en)	2017-11-01
IL286835B1 (en)	2023-11-01
CN113105553B (zh)	2024-09-10
IL252811B (en)	2021-10-31
CN113105553A (zh)	2021-07-13
KR102548827B1 (ko)	2023-06-30
NZ732628A (en)	2019-01-25
EP3237006A4 (en)	2018-05-30
JP2018509175A (ja)	2018-04-05
IL252811A0 (en)	2017-08-31
SMT202400477T1 (it)	2025-01-14
CN113105551B (zh)	2024-10-25
CN106659779B (zh)	2021-05-18
CN113512120A (zh)	2021-10-19
WO2016106158A1 (en)	2016-06-30
JP7335290B2 (ja)	2023-08-29
EP3237005B1 (en)	2024-09-18
EP4491195A2 (en)	2025-01-15
CN113512123A (zh)	2021-10-19
CA2969867A1 (en)	2016-06-30
CN106659779A (zh)	2017-05-10
US10919977B2 (en)	2021-02-16
PT3237005T (pt)	2024-11-18
JP2021119149A (ja)	2021-08-12
LT3237005T (lt)	2024-11-11
AU2015369831B2 (en)	2019-07-11
KR20170091162A (ko)	2017-08-08
US20170369587A1 (en)	2017-12-28
IL286835A (en)	2021-10-31
CN113512122A (zh)	2021-10-19
CN113512122B (zh)	2024-09-10
PL3237005T3 (pl)	2025-01-27
HRP20241502T1 (hr)	2025-01-03
CN113150165A (zh)	2021-07-23
CN113512121B (zh)	2024-10-25
CN117467017A (zh)	2024-01-30
KR20230104988A (ko)	2023-07-11
US10717783B2 (en)	2020-07-21
AU2015369831A1 (en)	2017-06-29
CN113512123B (zh)	2024-10-25
CN113105552B (zh)	2024-09-20
CN113150165B (zh)	2024-09-03
EP4491195A3 (en)	2025-04-02
CN107206074A (zh)	2017-09-26
FI3237005T3 (fi)	2024-12-02
EP3237005A4 (en)	2018-05-23
CA2969867C (en)	2022-01-25
SG11201704741PA (en)	2017-07-28
RS66070B1 (sr)	2024-11-29
KR20230149328A (ko)	2023-10-26
CN113105551A (zh)	2021-07-13
HUE069256T2 (hu)	2025-02-28
CN113105552A (zh)	2021-07-13
IL305193A (en)	2023-10-01
CN113512121A (zh)	2021-10-19
EP3237006A1 (en)	2017-11-01

Publication	Publication Date	Title
IL286835A (en)	2021-10-31	Bispecific tetravalent antibodies and methods for their preparation and use
HK1244492A1 (zh)	2018-08-10	抗pd-1抗體及其使用方法
HK1243102A1 (zh)	2018-07-06	抗cd79b抗體和使用方法
HRP20181359T1 (hr)	2018-10-19	Anti-jagged1 protutijela i postupci uporabe
IL251868A0 (en)	2017-06-29	Anti-tim3 antibodies and methods of use
ZA201606630B (en)	2020-12-23	Anti-ox40 antibodies and methods of use
IL248399A0 (en)	2016-11-30	New anti-43rnf antibodies and methods of use
ZA201701674B (en)	2019-09-25	Novel anti-mfi2 antibodies and methods of use
IL251165A0 (en)	2017-04-30	Anti-il-1beta antibodies and methods of their use
IL251286A0 (en)	2017-05-29	Anti-pdgf-b antibodies and methods of use